Side-by-side · Research reference
P21vsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BPhase 3HUMAN-REVIEWED25/54 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
P21
Survodutide
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
—
—
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
—
Antibody development
—
—
02Dosage Protocols
Parameter
P21
Survodutide
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Phase 2 RCT (obesity) · Phase 3 ongoing
Duration
Not specified
—
Frequency
—
Once weekly
03Metabolic / Fat Loss Evidence
Parameter
P21
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
P21
Survodutide
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
GI symptoms
—
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
P21
- ·Use in humans not validated
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
P21
Survodutide
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Timing
—
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage
—
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
—
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.